Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type

@article{Meyer1990ClinicalIO,
  title={Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type},
  author={J. W. Meyer and Brigitte Woggon and Pierre Baumann and Urs A. Meyer},
  journal={European Journal of Clinical Pharmacology},
  year={1990},
  volume={39},
  pages={613-614}
}
Sir, Since the first descriptions of the genetic polymorphism of debrisoquine [1] and sparteine [2], knowledge about genetic drug oxidation deficiency involving cytochrome P450dbl [3] has steadily grown. An impaired metabolism of more than 20 commonly prescribed drugs due to this deficiency has been described [4]. Poor metabolizers are at high risk to develop concentration-dependent adverse effects from these and probably many other drugs [1, 3, 4, 5]. The poor metabolizer phenotype behaves as… CONTINUE READING